Press Release |
| February 18, 2003 |
Daiichi Suntory Pharma Co., Ltd.
Zeria Pharmaceutical Co., Ltd.
Daiichi Pharmaceutical Co., Ltd.
|
| |
Daiichi Suntory Pharma, Zeria Pharmaceutical and Daiichi Pharmaceutical Agreed on Sales and Marketing of the Acute Heart Failure Agent HANP®Injection 1000 |
With reference to the exclusive marketing rights concerning the acute heart failure agent HANP® Injection 1000 in Japan owned by Zeria Pharmaceutical, based on the basic sales and marketing agreement dated May 28, 1994 entered between Daiichi Suntory Pharma and Zeria Pharmaceutical, Daiichi Suntory Pharma, Zeria Pharmaceutical and Daiichi Pharmaceutical agreed to newly grant sublicense to Daiichi Pharmaceutical from April 1, 2003.
Under this agreement, all the HANP® Injection 1000 products manufactured by Daiichi Suntory Pharma are purchased by Zeria, and repurchased by Daiichi Pharmaceutical, and then marketed by Daiichi Pharmaceutical with co-promotion aid by Zeria.
Reference
| Product: |
HANP® Injection 1000 |
| Composition: |
Carperitide (genetic recombination), 1000 g per vial |
| Indications: |
Acute heart failure including acute exacerbation of chronic heart failure |
| NHI price: |
Yen 2,996 per vial |
| Past sales results by Zeria: |
Yen 2,752 million (FY 1999 ended March 2000)
Yen 3,371 million (FY 2000 ended March 2001)
Yen 3,883 million (FY 2001 ended March 2002) |
| Characterstics: |
Alfa-human atrial natriuretic peptide, a kind of hormone regulating volume and circulation of the body fluid, was successfully cloned by Suntory Limited in 1984, and has been manufactured by the company and available for medical use as an  - human atrial natriuretic peptide (generic name: carperitide) preparation using a genetic recombination technology since 1995. |
|
|
|
|
|
